Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

@article{Kasper2010EfficacyOT,
  title={Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.},
  author={Siegfried Kasper and Goeran Hajak and Katharina Wulff and Witte J. G. Hoogendijk and {\'A}ngel L Montejo and Enrico Smeraldi and Janusz K Rybakowski and Maria-Antonia Quera-Salva and Anna M Wirz-Justice and Françoise Picarel-Blanchot and Franck Bayle},
  journal={The Journal of clinical psychiatry},
  year={2010},
  volume={71 2},
  pages={109-20}
}
OBJECTIVE This study evaluates the efficacy of agomelatine, the first antidepressant to be an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptors, versus sertraline with regard to the amplitude of the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder (MDD). METHOD Outpatients with DSM-IV-TR-defined MDD received either agomelatine 25 to 50 mg (n = 154) or sertraline 50 to 100 mg (n = 159) during a 6-week… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 93 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Antidepressant efficacy of agomelatine 25 – 50 mg versus venlafaxine 75 – 150 mg : two randomized , double - blind studies

  • SH Kennedy, C Guilleminault
  • J Clin Psychiatry
  • 2009

Similar Papers

Loading similar papers…